Crispr Therapeutics AG (NASDAQ: CRSP) — Perfil da empresa, notícias e dados financeiros
Crispr Therapeutics AG pioneers gene-based medicines for serious diseases, focusing on CRISPR/Cas9 technology.
Crispr Therapeutics AG
Crispr Therapeutics AG (NASDAQ:CRSP) is a biotechnology firm, pioneering the development of transformative gene-based medicines for serious human diseases. Using its proprietary CRISPR/Cas9 platform, Crispr Therapeutics focuses on the discovery, development, and commercialization of powerful therapies for the treatment of hematologic diseases, solid tumors, and rare diseases. The company's objective is to revolutionize treatment paradigms and improve patient outcomes through precision gene editing, embodying the next frontier in medical science. Crispr's dedication to innovation is exemplified by its diverse pipeline of investigational therapies and its collaborations with leading pharmaceutical companies to accelerate the development and delivery of groundbreaking treatments to patients worldwide.
Resumo
Operações
Produtos e/ou serviços de Crispr Therapeutics AG
- CTX001, a therapy for treating beta thalassemia and sickle cell disease through a partnership with Vertex Pharmaceuticals.
- CTLA-4, an oncology program targeting solid tumors and hematologic malignancies.
- BCMA, a CAR-T therapy for multiple myeloma, part of their immuno-oncology portfolio.
- VLA15, a vaccine candidate against Lyme disease developed in collaboration with Pfizer.
- CTX110, a wholly-owned CAR-T cell therapy aimed at treating CD19+ malignancies including non-Hodgkin lymphoma.
- CTX130, a CAR-T therapy for solid tumors and certain hematologic cancers.
equipe executiva do Crispr Therapeutics AG
- Samarth KulkarniCEO & Chairman
- Raju Yashaswi PrasadChief Financial Officer
- James R. KasingerGeneral Counsel & Secretary
- Naimish PatelChief Medical Officer
- Shaun FoyCo-Founder
- Emmanuelle Marie CharpentierCo-Founder & Scientific Advisory Board Member
- Craig C. MelloScientific Founder & Advisory Board Member
- Chad A. CowanScientific Founder
- Matthew PorteusScientific Founder & Advisory Board Member
- Stephen KennedyHead of Technical Operations
Principais indicadores financeiros
Resultados divulgados pela Crispr Therapeutics AG, em USD.
- Cap. de mercado
- 5,2 bi
- Receita (TTM)
- 13,4 mi
- P/L
- —
- LPA (diluído, TTM)
- -4.7
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 3,5 mi | -568,3 mi | -581,6 mi | |
| 35 mi | -466,6 mi | -366,3 mi | |
| 370 mi | -222,5 mi | -153,6 mi | |
| 436 mil | -673,2 mi | -650,2 mi |